Stock Ratings / Health Care / SYRE / dividends

MDGL (39) BMRN (67) PTGX (63) CORT (64) ⌘ Pro Terminal →

Spyre Therapeutics Inc. (SYRE) Dividend Safety Gauge & 10-Year DRIP Compounder

$98.96 -0.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Spyre Therapeutics Inc. (SYRE) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $10.33B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SYRE)Realized 20D OHLCV Swing Band: ±11.4%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (10.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $26,654

Est. Year-10 Shareholder Yield: $160/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.0K

Yr 1

$12.2K

Yr 2

$13.4K

Yr 3

$14.8K

Yr 4

$16.3K

Yr 5

$18.0K

Yr 6

$19.9K

Yr 7

$21.9K

Yr 8

$24.2K

Yr 9

$26.7K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SYRE)

✓Walkthrough of SYRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SYRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.15%⚡ TESTING RESISTANCE

2026-11-01O $99.75H $99.75L $98.96C $98.96VOL 567.7K

RES: $100.0SUP: $77.94SMA50: $89.91SMA200: $73.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SYRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SYRE Butterfly Map → + Track SYRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

15.7%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SYRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SYRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SYRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SYRE)

Health Care Rank #128 of 188 ⚔️ MDGL vs SYRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SYRE vs. MDGL, BMRN, PTGX, CORT)

Industry: Biotechnology: Pharmaceutical Preparations (64 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Spyre Therapeutics Inc. (SYRE) ranks #128 by composite RQD confidence (55/100, grade D+) and #110 by equity capitalization ($10.33B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while BMRN leads on capital efficiency and profitability with 6.0% ROIC and 77.7% gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with SYRE at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SYRE ACTIVE Spyre Therapeutics Inc.	D+	55/100	—	—	-20.0%	-0.79%	$10.33B	Benchmark Subject
MDGL Madrigal Pharmaceuticals Inc.	D-	39/100	—	—	-29.7%	+0.16%	$9.97B	/mdgl-vs-syre →
BMRN BioMarin Pharmaceutical Inc.	C+	67/100	31.9x	77.7%	6.0%	+2.66%	$11.13B	/bmrn-vs-syre →
PTGX Protagonist Therapeutics Inc.	C	63/100	—	—	-16.7%	+1.55%	$9.34B	/ptgx-vs-syre →
CORT Corcept Therapeutics Incorporated	C	64/100	93.2x	96.0%	4.8%	-0.38%	$9.29B	/cort-vs-syre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636282

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spyre Therapeutics Inc. (SYRE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$155.2M, operating cash flow of -$169.3M, and free cash flow of -$169.3M (-7.5% YoY). On the balance sheet, SYRE closed FY2025 with $777.8M in total assets against $28.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$155.2M	-$169.3M	-$169.3M	$777.8M	$28.1M
FY2024 (FY)	2024-12-31	$0	-$208.0M	-$157.4M	-$157.4M	$608.5M	$40.8M
FY2023 (FY)	2023-12-31	$886.0K	-$338.8M	-$99.9M	-$99.9M	$5.68B	$1.33B

3. SYRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SYRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Spyre Therapeutics Inc. (NASDAQ: SYRE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $98.96 (-0.79% 1D, market cap $10.33B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 188 tracked Health Care issuers, SYRE ranks #128 in composite RQD confidence.

How does SYRE compare to MDGL and BMRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SYRE carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.0%. By comparison, MDGL (Madrigal Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -29.7%, cap $9.97B) and BMRN (BioMarin Pharmaceutical Inc.) posts a C+ grade (67/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.13B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while BMRN leads on capital efficiency (6.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SYRE?

Per SYRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636282), Spyre Therapeutics Inc. generated $0 in revenue, -$155.2M in net income, and -$169.3M in free cash flow against $777.8M in total assets and $28.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SYRE trading relative to its 50-day, 200-day, and 52-week technical levels?

SYRE last traded at $98.96 (-0.79% on volume of 567,679 shares), positioning the stock +10.07% above its 50-day simple moving average ($89.91) and +34.55% above its 200-day simple moving average ($73.55). Across its 52-week range of $21.15 to $110.18, SYRE sits at the 87.4% percentile with a 14-day RSI of 61.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.4% ($87.68 to $110.24).

SYRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SYRE pay a dividend and is it safe?

Spyre Therapeutics Inc. (SYRE) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SYRE RQD Cockpit SYRE 12M Forecast SYRE Earnings & Move SYRE Dividends & DRIP SYRE Insiders & 13F SYRE Whale Options SYRE Profit Sankey SYRE News & Why